Filter Results:
(2,462)
Show Results For
- All HBS Web
(2,462)
- People (6)
- News (577)
- Research (1,760)
- Events (11)
- Multimedia (14)
- Faculty Publications (1,391)
Show Results For
- All HBS Web
(2,462)
- People (6)
- News (577)
- Research (1,760)
- Events (11)
- Multimedia (14)
- Faculty Publications (1,391)
- April 2011 (Revised March 2012)
- Supplement
U.S. Healthcare Reform: Reaction to the Patient Protection and Affordable Care Act of 2010
By: Arthur A. Daemmrich
Supplement to "U.S. Healthcare Reform: International Perspectives" updating key events and disputes concerning the reform law, including the 2010 Congressional elections, legislative proposals, legal challenges, and responses by employers. View Details
Keywords: Governing Rules, Regulations, and Reforms; Government Legislation; Political Elections; Health Care and Treatment; Lawsuits and Litigation; Business and Government Relations; Public Opinion; Health Industry; Public Administration Industry; United States
Daemmrich, Arthur A. "U.S. Healthcare Reform: Reaction to the Patient Protection and Affordable Care Act of 2010." Harvard Business School Supplement 711-103, April 2011. (Revised March 2012.)
- fall 1995
- Article
Standard Setting Consortia, Antitrust, and High-Technology Industries
By: James J. Anton and Dennis A. Yao
Examines the antitrust treatment of private-sector standard setting in the U.S. Applicability of law and decision-making issues in high technology industries; Examination of cost-based facilitating theory; Approach to evaluate the reasonableness of a standard. View Details
Keywords: Private Sector; Information Technology; Law; Decision Making; Cost; Theory; Performance Evaluation; Standards; United States
Anton, James J., and Dennis A. Yao. "Standard Setting Consortia, Antitrust, and High-Technology Industries." Antitrust Law Journal 64, no. 1 (fall 1995): 247–265. (Harvard users click here for full text.)
- May 2023 (Revised June 2023)
- Case
Novartis (A): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Care and Treatment; Business Model; Leadership; Pharmaceutical Industry; Switzerland
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (A): Reimagining Medicine." Harvard Business School Case 723-443, May 2023. (Revised June 2023.)
- 23 Aug 2006
- Op-Ed
The Real Wal-Mart Effect
the world's largest company, primarily focused on its treatment of workers. The recent spate of books on the company is no exception. Some are overtly critical, for example... View Details
- 26 May 2020
- News
Perspectives in Health: Cleveland Clinic - Building an Agile Org. in the Age of COVID-19
Keywords: COVID-19
- 30 Aug 2020
- Working Paper Summaries
Consumers Punish Firms that Cut Employee Pay in Response to COVID-19
- February 2025
- Article
Variation in Batch Ordering of Imaging Tests in the Emergency Department and the Impact on Care Delivery
By: Jacob C. Jameson, Soroush Saghafian, Robert S. Huckman and Nicole Hodgson
Objectives: To examine heterogeneity in physician batch ordering practices and measure the impact of a physician's tendency to batch order imaging tests on patient outcomes and resource utilization.
Study Setting and Design: In this retrospective study, we used... View Details
Study Setting and Design: In this retrospective study, we used... View Details
Keywords: Health Care; Operations Management; Productivity; Health Care and Treatment; Operations; Outcome or Result; Resource Allocation; Health Industry; United States
Jameson, Jacob C., Soroush Saghafian, Robert S. Huckman, and Nicole Hodgson. "Variation in Batch Ordering of Imaging Tests in the Emergency Department and the Impact on Care Delivery." Health Services Research 60, no. 1 (February 2025).
Population Interference in Panel Experiments
The phenomenon of population interference, where a treatment assigned to one experimental unit affects another experimental unit’s outcome, has received considerable attention in standard randomized experiments. The complications produced by population... View Details
- October 2009 (Revised August 2014)
- Case
Tengion: Bringing Regenerative Medicine to Life
By: Elie Ofek and Polly Ross Ribatt
Tengion is a young biotech company that is at the frontier of regenerative medicine—a nascent field that seeks to promote the creation of new cells and tissue to repair or replace tissue or organ function lost due to age, disease, damage, or congenital defects. In late... View Details
Keywords: Decision Choices and Conditions; Financial Crisis; Entrepreneurship; Health Care and Treatment; Technological Innovation; Product Launch; Product Development; Research and Development; Biotechnology Industry; United States
Ofek, Elie, and Polly Ross Ribatt. "Tengion: Bringing Regenerative Medicine to Life." Harvard Business School Case 510-031, October 2009. (Revised August 2014.)
- 2019
- Chapter
Characterizing the Drug Development Pipeline for Precision Medicines
By: Amitabh Chandra, Craig Garthwaite and Ariel Dora Stern
BOOK ABSTRACT: Personalized and precision medicine (PPM)—the targeting of therapies according to an individual’s genetic, environmental, or lifestyle characteristics—is becoming an increasingly important approach in health care treatment and prevention. The advancement... View Details
Chandra, Amitabh, Craig Garthwaite, and Ariel Dora Stern. "Characterizing the Drug Development Pipeline for Precision Medicines." Chap. 5 in Economic Dimensions of Personalized and Precision Medicine, edited by Ernest R. Berndt, Dana P. Goldman, and John W. Rowe, 115–158. University of Chicago Press, 2019.
- 2023
- Article
Comparison of COVID-19 Hospitalization Costs across Care Pathways: A Patient-level Time-driven Activity-based Costing Analysis in a Brazilian Hospital
By: Ricardo Bertoglio Cardoso, Miriam Allein Zago Marcolino, Milena Soriano Marcolino, Camila Felix Fortis, Leila Beltrami Moreira, Ana Paula Coutinho, Nadine Oliveira Clausell, Junaid Nabi, Robert S. Kaplan, Ana Paula Beck da Silva Etges and Carisi Anne Polanczyk
The COVID-19 pandemic raised awareness of the need to better understand where and how patient-level costs are incurred in health care organizations. This study used time-driven activity-based costing to estimate COVID-19 patient-level hospital costs in a Brazilian... View Details
Cardoso, Ricardo Bertoglio, Miriam Allein Zago Marcolino, Milena Soriano Marcolino, Camila Felix Fortis, Leila Beltrami Moreira, Ana Paula Coutinho, Nadine Oliveira Clausell, Junaid Nabi, Robert S. Kaplan, Ana Paula Beck da Silva Etges, and Carisi Anne Polanczyk. "Comparison of COVID-19 Hospitalization Costs across Care Pathways: A Patient-level Time-driven Activity-based Costing Analysis in a Brazilian Hospital." BMC Health Services Research 23, no. 198 (2023).
- 12 Dec 2022
- Research & Ideas
Buy-In from Black Patients Suffers When Drug Trials Don’t Include Them
Black patients and their doctors may be more open to new medications if drug trials included more Black people, new research shows. Currently, Black Americans represent just 5 percent of drug trial participants. Nearly three-quarters... View Details
- 2021
- Working Paper
Population Interference in Panel Experiments
By: Iavor I Bojinov, Kevin Wu Han and Guillaume Basse
The phenomenon of population interference, where a treatment assigned to one experimental unit affects another experimental unit's outcome, has received considerable attention in standard randomized experiments. The complications produced by population interference in... View Details
Bojinov, Iavor I., Kevin Wu Han, and Guillaume Basse. "Population Interference in Panel Experiments." Harvard Business School Working Paper, No. 21-100, March 2021.
- May 2023 (Revised June 2023)
- Supplement
Novartis (B): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Care and Treatment; Business Model; Production; Business Strategy; Pharmaceutical Industry
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (B): Reimagining Medicine." Harvard Business School Supplement 723-444, May 2023. (Revised June 2023.)
- April 29, 2024
- Editorial
Stemming the Ripple Effect of Untreated Mental Illness: A Prescription for Change: Reimagining U.S. Healthcare
By: Lidia Moura and Susanna Gallani
Moura, Lidia, and Susanna Gallani. "Stemming the Ripple Effect of Untreated Mental Illness: A Prescription for Change: Reimagining U.S. Healthcare." Psychology Today (website) (April 29, 2024).
- 17 Nov 2016
- Cold Call Podcast
Building Affordable Health Care in Paradise
- September 2009
- Article
A Detailed Analysis of the Reduction Mammaplasty Learning Curve: A Statistical Process Model for Approaching Surgical Performance Improvement
By: Matthew Carty MD, Rodney Chan, Robert S. Huckman, Daniel C. Snow and Dennis Orgill
Background: The increased focus on quality and efficiency improvement within academic surgery has met with variable success among plastic surgeons. Traditional surgical performance metrics, such as morbidity and mortality, are insufficient to improve the... View Details
Keywords: Experience and Expertise; Health Care and Treatment; Medical Specialties; Outcome or Result; Performance Efficiency; Performance Improvement
Carty, Matthew, MD, Rodney Chan, Robert S. Huckman, Daniel C. Snow, and Dennis Orgill. "A Detailed Analysis of the Reduction Mammaplasty Learning Curve: A Statistical Process Model for Approaching Surgical Performance Improvement." Plastic and Reconstructive Surgery 124, no. 3 (September 2009): 706–714.
- 2023
- Working Paper
'De Gustibus' and Disputes about Reference Dependence
By: Thomas Graeber, Pol Campos-Mercade, Lorenz Goette, Alexandre Kellogg and Charles Sprenger
Existing tests of reference-dependent preferences assume universal loss aversion. This paper examines the implications of heterogeneity in gain-loss attitudes for such tests. In experiments on labor supply and exchange behavior we measure gain-loss attitudes and then... View Details
Graeber, Thomas, Pol Campos-Mercade, Lorenz Goette, Alexandre Kellogg, and Charles Sprenger. "'De Gustibus' and Disputes about Reference Dependence." Harvard Business School Working Paper, No. 24-046, January 2024.
- Article
Resilience vs. Vulnerability: Psychological Safety and Reporting of Near Misses with Varying Proximity to Harm in Radiation Oncology
By: Palak Kundu, Olivia Jung, Amy C. Edmondson, Nzhde Agazaryan, John Hegde, Michael Steinberg and Ann Raldow
Background
Psychological safety, a shared belief that interpersonal risk taking is safe, is an important determinant of incident reporting. However, how psychological safety affects near-miss reporting is unclear, as near misses contain contrasting cues that... View Details
Psychological safety, a shared belief that interpersonal risk taking is safe, is an important determinant of incident reporting. However, how psychological safety affects near-miss reporting is unclear, as near misses contain contrasting cues that... View Details
Kundu, Palak, Olivia Jung, Amy C. Edmondson, Nzhde Agazaryan, John Hegde, Michael Steinberg, and Ann Raldow. "Resilience vs. Vulnerability: Psychological Safety and Reporting of Near Misses with Varying Proximity to Harm in Radiation Oncology." Joint Commission Journal on Quality and Patient Safety 47, no. 1 (January 2021): 15–22.